APOBEC3B: Pathological consequences of an innate immune DNA mutator

Biomedical Journal

Volumn 38, Issue 2, 2015, Pages 102-110

  Burns, Michael B ^a,b   Leonard, Brandon ^a,b,c,d   Harris, Reuben S ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

APOBEC3B; Cancer; DNA cytosine deamination; Genomic uracil; Mutation

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; CYTOSINE; CYTOSINE DEAMINASE; GENOMIC DNA; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; URACIL; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; DNA; MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLELE; AMINO ACID SUBSTITUTION; APOBEC3B GENE; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RESEARCH; CHROMOSOME ABERRATION; DEAMINATION; DISEASE ASSOCIATION; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GENE DELETION; GENE DUPLICATION; GENE LOCUS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOME; HEAD AND NECK CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LUNG ADENOCARCINOMA; MISMATCH REPAIR; MUTAGENESIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SQUAMOUS CELL LUNG CARCINOMA; UTERINE CERVIX CANCER; VIRUS IMMUNITY; WART VIRUS; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY;

ANIMALS; CYTIDINE DEAMINASE; DNA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; MUTATION; NEOPLASMS;

EID: 84928564208     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.148904     Document Type: Article

References (62)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
2. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012;149:979-93.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
4. Alexandrov LB, Stratton MR. Mutational signatures: The patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014;24:52-60.
5. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485:502-6.
6. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-6.
7. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
8. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004;38:445-76.
9. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013;494:366-70.
10. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013;45:977-83.
11. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, et al . APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res 2013;73:7222-31.
12. Sieuwerts AM, Willis S, Burns MB, Look MP, Gelder ME, Schlicker A, et al . Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. Horm Cancer 2014;5:405-13.
13. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, et al . APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2012;2:806.
14. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, et al . DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2013;2:e00534.
15. Ehrlich M, Norris KF, Wang RY, Kuo KC, Gehrke CW. DNA cytosine methylation and heat-induced deamination. Biosci Rep 1986;6:387-93.
16. Conticello SG. The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008;9:229.
17. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002;10:1247-53.
18. LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, Emerman M, et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 2009;83:494-7.
19. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007;76:1-22.
20. Vieira VC, Soares MA. The role of cytidine deaminases on innate immune responses against human viral infections. BioMed Res Int 2013;2013:683095.
21. Koito A, Ikeda T. Apolipoprotein B mRNA-editing, catalytic polypeptide cytidine deaminases and retroviral restriction. Wiley Interdiscip Rev RNA 2012;3:529-41.
22. Schmitz KM, Petersen-Mahrt SK. AIDing the immune system-DIAbolic in cancer. Semin Immunol 2012;24:241-5.
23. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012;287:40875-83.
24. Refsland EW, Harris RS. The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 2013;371:1-27.
25. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 2011;85:11220-34.
26. Refsland EW, Hultquist JF, Harris RS. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog 2012;8:e1002800.
27. Carpenter MA, Li M, Rathore A, Lackey L, Law EK, Land AM, et al . Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem 2012;287:34801-8.
28. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 2006;34:89-95.
29. Stenglein MD, Harris RS. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem 2006;281:16837-41.
30. Bulliard Y, Narvaiza I, Bertero A, Peddi S, Röhrig UF, Ortiz M, et al. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol 2011;85:1765-76.
31. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 2010;17:222-9.
32. Liu L, De S, Michor F. DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nat Commun 2013;4:1502.
33. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
34. Adam S, Polo SE. Blurring the line between the DNA damage response and transcription: The importance of chromatin dynamics. Exp Cell Res 2014;329:148-53.
35. LaRue RS, Jónsson SR, Silverstein KA, Lajoie M, Bertrand D, El-Mabrouk N, et al. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol 2008;9:104.
36. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: Implications for HIV-1 restriction. Nucleic Acids Res 2010;38:4274-84.
37. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009;83:9474-85.
38. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 1995;92:8483-7.
39. Saraconi G, Severi F, Sala C, Mattiuz G, Conticello SG. The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol 2014;15:417.
40. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002;418:99-103.
41. Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, et al . APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest 2011;121:4526-36.
42. Okazaki I, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, et al. Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003;197:1173-81.
43. Robbiani DF, Nussenzweig MC. Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 2013;8:79-103.
44. Ramiro AR, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M, et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004;118:431-8.
45. Lackey L, Demorest ZL, Land AM, Hultquist JF, Brown WL, Harris RS. APOBEC3B and AID have similar nuclear import mechanisms. J Mol Biol 2012;419:301-14.
46. Land AM, Law EK, Carpenter MA, Lackey L, Brown WL, Harris RS. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J Biol Chem 2013;288:17253-60.
47. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al . An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013;45:970-6.
48. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
49. Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, et al . APOBEC3 signature mutations in chronic lymphocytic leukemia. Leukemia 2014;28:1929-32.
50. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 2014;7:1833-41.
51. Krokan HE, Sætrom P, Aas PA, Pettersen HS, Kavli B, Slupphaug G. Error-free versus mutagenic processing of genomic uracil-relevance to cancer. DNA Repair 2014;19:38-47.
52. Chan K, Resnick MA, Gordenin DA. The choice of nucleotide inserted opposite abasic sites formed within chromosomal DNA reveals the polymerase activities participating in translesion DNA synthesis. DNA Repair 2013;12:878-89.
53. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 2007;3:e63.
54. Komatsu A, Nagasaki K, Fujimori M, Amano J, Miki Y. Identification of novel deletion polymorphisms in breast cancer. Int J Oncol 2008;33:261-70.
55. Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 2013;34:2240-3.
56. Long J, Delahanty RJ, Li G, Gao YT, Lu W, Cai Q, et al. A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 2013;105:573-9.
57. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-73.
58. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 2014;46:487-91.
59. Koning FA, Goujon C, Bauby H, Malim MH. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol 2011;85:13448-52.
60. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, et al . APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006;16:480-5.
61. Zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009;384:260-5.
62. Harris RS. Enhancing immunity to HIV through APOBEC. Nat Biotechnol 2008;26:1089-90.